Compare Cytokinetics Inc (CYTK) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Iron Mountain Inc — how do they compare? Cytokinetics Inc trades at $76.66 (market cap $10.78B), while Iron Mountain Inc trades at $122.41 (market cap $36.19B). The key difference: Iron Mountain Inc is far larger — about 3.4× Cytokinetics Inc's market cap, and Iron Mountain Inc pays a 2.84% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | IRM | |
|---|---|---|
Market Cap | $10.78B | $36.19B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $133.06 |
52-Week Low | $34.31 | $78.86 |
Enterprise Value | $10.88B | $55.60B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
